Ascendis Pharma A/S (ASND) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ASND Revenue Growth
Revenue Breakdown
ASND's revenue distribution by segment and geography
By Geography
ASND Revenue Analysis (2014–2025)
As of May 7, 2026, Ascendis Pharma A/S (ASND) generated trailing twelve-month (TTM) revenue of $717.8 million, reflecting explosive growth of +41.0% year-over-year. The most recent quarter (Q4 2025) recorded $245.2 million in revenue, up 14.8% sequentially.
Looking at the longer-term picture, ASND's 5-year compound annual growth rate (CAGR) stands at +150.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $691.7 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including IONS (+47.5% YoY), INCY (+21.5% YoY), and ALKS (+3.2% YoY), ASND has underperformed the peer group in terms of revenue growth. Compare ASND vs IONS →
ASND Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ASNDCurrent | $718M | +41.0% | +150.9% | -18.9% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 INCY | $5.1B | +21.5% | +14.0% | 26.1% | |
 ALKS | $1.5B | +3.2% | +7.3% | 17.2% | |
 JAZZ | $4.3B | +9.2% | +12.5% | 5.3% | |
 ACAD | $1.1B | +11.9% | +19.4% | 9.8% |
ASND Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $691.7M | +90.2% | $588.5M | 85.1% | $-130,892,766 | -18.9% |
| 2024 | $363.6M | +36.3% | $319.4M | 87.8% | $-278,763,000 | -76.7% |
| 2023 | $266.7M | +421.2% | $222.3M | 83.4% | $-455,541,000 | -170.8% |
| 2022 | $51.2M | +557.9% | $39.0M | 76.3% | $-561,814,000 | -1097.9% |
| 2021 | $7.8M | +11.9% | $4.3M | 54.7% | $-451,792,000 | -5808.6% |
| 2020 | $7.0M | -48.0% | $7.0M | 100.0% | $-330,620,000 | -4755.1% |
| 2019 | $13.4M | +26.4% | $13.4M | 100.0% | $-226,719,000 | -1695.1% |
| 2018 | $10.6M | +591.6% | $10.6M | 100.0% | $-154,757,000 | -1462.6% |
| 2017 | $1.5M | -66.8% | $1.5M | 100.0% | $-111,541,000 | -7290.3% |
| 2016 | $4.6M | -43.3% | $4.6M | 100.0% | $-72,920,000 | -1583.2% |
Full ASND Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See ASND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ASND Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ASND vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonASND — Frequently Asked Questions
Quick answers to the most common questions about buying ASND stock.
Is ASND's revenue growth accelerating or slowing?
ASND revenue is accelerating at +41.0% year-over-year, exceeding the 5-year CAGR of +150.9%. TTM revenue reached $718M. Growth momentum has increased versus prior periods.
What is ASND's long-term revenue growth rate?
Ascendis Pharma A/S's 5-year revenue CAGR of +150.9% reflects the sustained expansion pattern. Current YoY growth of +41.0% is above this long-term average.
How is ASND's revenue distributed by segment?
ASND reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.